Diabetic Nephropathy: a Tangled Web to Unweave

    Research output: Contribution to journalArticle

    Early online date

    View graph of relations

    Diabetic nephropathy (DN) is currently the leading cause of end-stage renal disease globally. Given the increasing incidence of diabetes, many experts hold the view that DN will eventually progress toward pandemic proportions. Whilst hyperglycaemia-induced vascular dysfunction is the primary initiating mechanism in DN, its progression is also driven by a heterogeneous set of pathological mechanisms, including oxidative stress, inflammation and fibrosis. Current treatment strategies for DN are targeted against the fundamental dysregulation of glycaemia and hypertension. Unfortunately, these standards of care can delay but do not prevent disease progression or the significant emotional, physical and financial costs associated with this disease. As such, there is a pressing need to develop novel therapeutics that are both effective and safe. Set against the genomic era, numerous potential target pathways in DN have been identified. However, the clinical translation of basic DN research has been met with a number of challenges. Moreover, the notion of DN as a purely vascular disease is outdated and it has become clear that DN is a multi-dimensional, multi-cellular condition. The review will highlight the current therapeutic approaches for DN and provide an insight into how the inherent complexity of DN is shaping the research pathways toward the development and clinical translation of novel therapeutic strategies.


    • Diabetic Nephropathy: a Tangled Web to Unweave

      Rights statement: © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

      Final published version, 743 KB, PDF-document


    Original languageEnglish
    Number of pages14
    Pages (from-to)1-14
    JournalCardiovascular Drugs and Therapy
    Journal publication date27 Sep 2017
    Early online date27 Sep 2017
    Publication statusEarly online date - 27 Sep 2017

      Research areas

    • Diabetic nephropathy, Inflammation, Novel therapies, Oxidative stress, Renin-angiotensin-aldosterone system, Vascular dysfunction

    ID: 138056561